25th World Congress of Dermatology (WCD Singapore 2023)
Singapore 03 July 2023 - 08 July 2023
Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea
Treatment with a microencapsulated benzoyl peroxide (E-BPO) 5% cream contributes to changes in the microbiome of the skin and results in improvements in moderate to severe rosacea, according to a study presented at the recent WCD 2023.
